NCT05238831 — drugset

Summary

SMMART-ACT is a feasibility pilot study to determine if testing samples from a participant's cancer using a precision medicine approach can be used to identify specific drugs or drug combinations that can help control their disease. The safety and tolerability of the drug or drug combination is also to be studied. Another purpose is for researchers to study tumor cells to try to learn why some people respond to a certain therapy and others do not, and why some cancer drugs stop working. The study population will include participants with advanced breast, ovarian, prostate, or pancreatic malignancies, or sarcomas.

Timeline

Start: 2023-01-30
Primary completion: 2026-05-31
Completion: 2026-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alectinib	Small molecule	—	Oral
Subject	Alpelisib	Small molecule	—	Oral
Subject	Anastrozole	Other / unclassified	—	Oral
Subject	Atezolizumab	Monoclonal antibody	—	Intravenous
Subject	Bevacizumab	Monoclonal antibody	—	Intravenous
Subject	Capecitabine	Small molecule	—	Oral
Subject	Carboplatin	Small molecule	—	Intravenous
Subject	Cobimetinib	Small molecule	—	Oral
Subject	Entrectinib	Small molecule	—	Oral
Subject	Eribulin	Small molecule	—	Intravenous
Subject	Fulvestrant	Small molecule	—	Other
Subject	Irinotecan	Small molecule	—	Intravenous
Subject	Letrozole	Other / unclassified	—	Oral
Subject	Niraparib	Small molecule	—	Oral
Subject	Olaparib	Small molecule	—	Oral
Subject	Paclitaxel	Small molecule	—	Intravenous
Subject	Palbociclib	Small molecule	—	Intravenous
Subject	Pertuzumab	Monoclonal antibody	—	Subcutaneous
Subject	Trastuzumab	Monoclonal antibody	—	Subcutaneous
Subject	Trastuzumab emtansine	Other / unclassified	—	Intravenous
Subject	Vemurafenib	Small molecule	—	Oral
Subject	Vinorelbine	Small molecule	—	Intravenous
Subject	Vismodegib	Small molecule	—	Oral
Subject	rHuPH20	Protein / enzyme biologic	—	Subcutaneous

SMMART Adaptive Clinical Treatment (ACT) Trial

Summary

Timeline

Drugs

Indications